{"id":"oral-suzetrigine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5314487","moleculeType":"Small molecule","molecularWeight":"473.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Suzetrigine selectively inhibits voltage-gated sodium channels, particularly in pain-sensing neurons, thereby reducing the generation and propagation of action potentials involved in pain signaling. By blocking sodium influx, it dampens neuronal firing without significantly affecting normal motor or cognitive function, making it suitable for chronic pain management.","oneSentence":"Suzetrigine is a selective sodium channel blocker that reduces neuronal excitability and pain signal transmission.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:58:53.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain conditions (specific indication pending confirmation of marketed status)"}]},"trialDetails":[{"nctId":"NCT07463430","phase":"PHASE4","title":"Suzetrigine for Non-Mastectomy Breast Surgery","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-03-30","conditions":"Pain, Acute Postoperative, Breast Disease","enrollment":120},{"nctId":"NCT07231419","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-11-21","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":734},{"nctId":"NCT07378865","phase":"PHASE1","title":"Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-02-13","conditions":"Pain","enrollment":12},{"nctId":"NCT06628908","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-10-01","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":1100},{"nctId":"NCT06696443","phase":"PHASE3","title":"Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-12-18","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":455},{"nctId":"NCT07357376","phase":"PHASE3","title":"Evaluating Suzetrigine for Pain Control Following TKA","status":"NOT_YET_RECRUITING","sponsor":"AdventHealth","startDate":"2026-03-01","conditions":"Postoperative Pain Following Knee Arthroplasty","enrollment":210},{"nctId":"NCT06887972","phase":"PHASE4","title":"A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-21","conditions":"Acute Pain","enrollment":100},{"nctId":"NCT06887959","phase":"PHASE4","title":"A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-27","conditions":"Acute Pain","enrollment":47},{"nctId":"NCT07145346","phase":"PHASE4","title":"Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Irvine","startDate":"2025-11-13","conditions":"Rib Fractures","enrollment":80},{"nctId":"NCT07257133","phase":"PHASE4","title":"A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03","conditions":"Post Operative Pain","enrollment":40},{"nctId":"NCT07219888","phase":"PHASE4","title":"Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"University of Louisville","startDate":"2025-12-01","conditions":"Osteoarthritis (OA) of the Knee","enrollment":140},{"nctId":"NCT06176196","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-13","conditions":"Painful Lumbosacral Radiculopathy","enrollment":218},{"nctId":"NCT07195669","phase":"PHASE4","title":"RCT: Suzetrigine vs Norco for Post-op Pain","status":"NOT_YET_RECRUITING","sponsor":"Jacob Lensing","startDate":"2025-10-01","conditions":"Pain Control","enrollment":76},{"nctId":"NCT05553366","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-10-03","conditions":"Acute Pain","enrollment":1075},{"nctId":"NCT05661734","phase":"PHASE3","title":"A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-01-09","conditions":"Pain","enrollment":258},{"nctId":"NCT05558410","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-10-10","conditions":"Acute Pain","enrollment":1118},{"nctId":"NCT05660538","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-12-20","conditions":"Diabetic Peripheral Neuropathy","enrollment":194},{"nctId":"NCT04977336","phase":"PHASE2","title":"A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-07-19","conditions":"Acute Pain","enrollment":274},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT06834009","phase":"PHASE1","title":"A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-03-10","conditions":"Pain","enrollment":10},{"nctId":"NCT05034952","phase":"PHASE2","title":"A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-08-30","conditions":"Acute Pain","enrollment":303},{"nctId":"NCT06336096","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-03-28","conditions":"Pain","enrollment":48},{"nctId":"NCT05704556","phase":"PHASE1","title":"Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-02-27","conditions":"Pain","enrollment":38},{"nctId":"NCT05818852","phase":"PHASE1","title":"A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-04-12","conditions":"Pain","enrollment":72},{"nctId":"NCT05455502","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-07-13","conditions":"Pain","enrollment":24},{"nctId":"NCT05560464","phase":"PHASE1","title":"Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-10-14","conditions":"Pain","enrollment":36},{"nctId":"NCT05541471","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-09-22","conditions":"Pain","enrollment":37},{"nctId":"NCT05635110","phase":"PHASE1","title":"Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-12-15","conditions":"Pain","enrollment":31},{"nctId":"NCT05851157","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-05-03","conditions":"Pain","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"oral suzetrigine","genericName":"oral suzetrigine","companyName":"University of Louisville","companyId":"university-of-louisville","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Suzetrigine is a selective sodium channel blocker that reduces neuronal excitability and pain signal transmission. Used for Chronic pain conditions (specific indication pending confirmation of marketed status).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}